Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season

MMWR Recommendations and Reports

Volumn 68, Issue 3, 2019, Pages 1-28

  Grohskopf, Lisa A ^a   Alyanak, Elif ^a,b   Broder, Karen R ^c   Walter, Emmanuel B ^d   Fry, Alicia M ^a   Jernigan, Daniel B ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ADVISORY COMMITTEE; AGED; CHILD; FEMALE; HUMAN; IMMUNIZATION; INFANT; INFLUENZA; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PREGNANCY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEASON; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; AGED; CENTERS FOR DISEASE CONTROL AND PREVENTION, U.S.; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEASONS; UNITED STATES; YOUNG ADULT;

EID: 85071466992     PISSN: 10575987     EISSN: 15458601     Source Type: Journal    
DOI: 10.15585/MMWR.RR6803A1     Document Type: Article

References (109)

1. 1. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970–78. Am J Public Health 1986;76:761–5. https://doi.org/10.2105/AJPH.76.7.761
2. 2. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798–811. https://doi.org/10.1093/oxfordjournals.aje.a113052
3. 3. Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza in young children, 2004–2009. Pediatrics 2013;131:207–16. https://doi.org/10.1542/peds.2012-1255
4. 4. Poehling KA, Edwards KM, Weinberg GA, et al; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med 2006;355:31–40. https://doi.org/10.1056/NEJMoa054869
5. 5. Siston AM, Rasmussen SA, Honein MA, et al; Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010;303:1517–25. https://doi.org/10.1001/jama.2010.479
6. 6. Mullooly JP, Bridges CB, Thompson WW, et al; Vaccine Safety Datalink Adult Working Group. Influenzaand RSV-associated hospitalizations among adults. Vaccine 2007;25:846–55. https://doi.org/10.1016/j.vaccine.2006.09.041
7. 7. Coleman BL, Fadel SA, Fitzpatrick T, Thomas SM. Risk factors for serious outcomes associated with influenza illness in highversus lowand middle-income countries: Systematic literature review and metaanalysis. Influenza Other Respir Viruses 2018;12:22–9. https://doi.org/10.1111/irv.12504
8. 8. Van Wormer JJ, King JP, Gajewski A, McLean HQ, Belongia EA. Influenza and Workplace Productivity Loss in Working Adults. J Occup Environ Med 2017;59:1135–9. https://doi.org/10.1097/JOM.0000000000001120
9. 9. Willis GA, Preen DB, Richmond PC, et al; WAIVE Study Team. The impact of influenza infection on young children, their family and the health care system. Influenza Other Respir Viruses 2019;13:18–27. https://doi.org/10.1111/irv.12604
10. 10. Fragaszy EB, Warren-Gash C, White PJ, et al; Flu Watch Group. Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: results from the Flu Watch cohort study. Influenza Other Respir Viruses 2018;12:171–82. https://doi.org/10.1111/irv.12506
11. 11. Fiore AE, Uyeki TM, Broder K, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8).
12. 12. CDC. How flu vaccine effectiveness and efficacy is measured: questions and answers. Atlanta, GA: US Department of Health and Human Services, CDC. https://www.cdc.gov/flu/professionals/vaccination/effectivenessqa.htm
13. 13. Rolfes MA, Foppa IM, Garg S, et al. Annual estimates of the burden of seasonal influenza in the United States: a tool for strengthening influenza surveillance and preparedness. Influenza Other Respir Viruses 2018;12:132–7. https://doi.org/10.1111/irv.12486
14. 14. Rolfes MA, Flannery B, Chung J, et al; US Flu VE Network, the Influenza Hospitalization Surveillance Network (FluSurv-NET), and the Assessment Branch, Immunization Services Division, CDC. Effects of Influenza Vaccination in the United States during the 2017–2018 Influenza Season. Clin Infect Dis 2019. https://doi.org/10.1093/cid/ciz075
15. 15. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018–19 Influenza Season. MMWR Recomm Rep 2018;67(No. RR-3). https://doi.org/10.15585/mmwr.rr6703a1
16. 16. CDC. The flu season. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. https://www.cdc.gov/flu/about/season/flu-season.htm
17. 17. Castilla J, Martínez-Baz I, Martínez-Artola V, et al; Primary Health Care Sentinel Network; Network for Influenza Surveillance in Hospitals of Navarre. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013;18:20388. https://doi.org/10.2807/ese.18.05.20388-en
18. 18. Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre casecontrol study. Euro Surveill 2013;18:20390. https://doi.org/10.2807/ese.18.05.20390-en
19. 19. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 2015;33:246–51. https://doi.org/10.1016/j.vaccine.2014.06.052
20. 20. Radin JM, Hawksworth AW, Myers CA, Ricketts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010–2011 through 2013–2014. Vaccine 2016;34:3907–12. https://doi.org/10.1016/j.vaccine.2016.05.034
21. 21. Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011–12 through 2014–15. Clin Infect Dis 2017;64:544–50.
22. 22. Puig-Barberà J, Mira-Iglesias A, Tortajada-Girbés M, et al; Valencia Hospital Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine 2017;35:5799–807. https://doi.org/10.1016/j.vaccine.2017.09.035
23. 23. Ray GT, Lewis N, Klein NP, et al. Intra-season waning of influenza vaccine effectiveness. Clin Infect Dis 2018.
24. 24. Kissling E, Nunes B, Robertson C, et al; I-MOVE case–control study team. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill 2016;21:30201. https://doi.org/10.2807/1560-7917.ES.2016.21.16.30201
25. 25. Pebody R, Andrews N, McMenamin J, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratoryconfirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 2013;18:20389. https://doi.org/10.2807/ese.18.05.20389-en
26. 26. Petrie JG, Ohmit SE, Truscon R, et al. Modest waning of influenza vaccine efficacy and antibody titers during the 2007–2008 influenza season. J Infect Dis 2016;214:1142–9. https://doi.org/10.1093/infdis/jiw105
27. 27. Ferdinands JM, Alyanak E, Reed C, Fry AM. Waning of influenza vaccine protection: Exploring the trade-offs of changes in vaccination timing among older adults. Clin Infect Dis 2019;ciz452. https://doi.org/10.1093/cid/ciz452
28. 28. Shefer A, Atkinson W, Friedman C, et al. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(No. RR-7).
29. 29. Pearson ML, Bridges CB, Harper SA. Influenza vaccination of healthcare personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(No. RR-2).
30. 30. Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SH, Karzon DT. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 1977;136(Suppl):S731–41. https://doi.org/10.1093/infdis/136.Supplement_3.S731
31. 31. Wright PF, Dolin R, La Montagne JR. Summary of clinical trials of influenza vaccines—II. J Infect Dis 1976;134:633–8. https://doi.org/10.1093/infdis/134.6.633
32. 32. Wright PF, Sell SH, Thompson J, Karzon DT. Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants. J Pediatr 1976;88:31–5. https://doi.org/10.1016/S0022-3476(76)80722-6
33. 33. Gross PA. Reactogenicity and immunogenicity of bivalent influenza vaccine in oneand two-dose trials in children: a summary. J Infect Dis 1977;136(Suppl):S616–25. https://doi.org/10.1093/infdis/136.Supplement_3.S616
34. 34. Bernstein DI, Zahradnik JM, DeAngelis CJ, Cherry JD. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics 1982;69:404–8.
35. 35. Jain VK, Domachowske JB, Wang L, et al. Time to change dosing of inactivated quadrivalent influenza vaccine in young children: evidence from a Phase III, randomized, controlled trial. J Pediatric Infect Dis Soc 2017;6:9–19. https://doi.org/10.1093/jpids/piw068
36. 36. Claeys C, Zaman K, Dbaibo G, et al; Flu4VEC Study Group. Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. Lancet Child Adolesc Health 2018;2:338–49. https://doi.org/10.1016/S2352-4642(18)30062-2
37. 37. Robertson CA, Mercer M, Selmani A, Klein NP, Jeanfreau R, Greenberg DP. Safety and immunogenicity of a full-dose, split-virion, inactivated, quadrivalent influenza vaccine in healthy children 6–35 months of age: a randomized controlled clinical trial. Pediatr Infect Dis J 2019;38:323–8. https://doi.org/10.1097/INF.0000000000002227
38. 38. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5–8-year-old children. J Infect Dis 2006;194:1032–9. https://doi.org/10.1086/507309
39. 39. Allison MA, Daley MF, Crane LA, et al. Influenza vaccine effectiveness in healthy 6-to 21-month-old children during the 2003–2004 season. J Pediatr 2006;149:755–62. https://doi.org/10.1016/j.jpeds.2006.06.036
40. 40. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003–2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 2005;116:153–9. https://doi.org/10.1542/peds.2005-0049
41. 41. Eisenberg KW, Szilagyi PG, Fairbrother G, et al; New Vaccine Surveillance Network. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003–2004 and 2004–2005 influenza seasons. Pediatrics 2008;122:911–9. https://doi.org/10.1542/peds.2007-3304
42. 42. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 732. Influenza vaccination during pregnancy. Obstet Gynecol 2018;131:e109–14 10.1097/AOG.0000000000002588. https://doi.org/10.1097/AOG.0000000000002588
43. 43. ACOG Infectious Disease and Public Health Preparedness Expert Work Group. ACOG Committee Opinion No. 741: Maternal Immunization. Obstet Gynecol 2018;131:e214–7 10.1097/AOG.0000000000002665. https://doi.org/10.1097/AOG.0000000000002662
44. 44. Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 2012;207:177.e1–8.
45. 45. Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1) v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012;30:4445–52. https://doi.org/10.1016/j.vaccine.2012.04.081
46. 46. Pasternak B, Svanström H, Mølgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 2012;344:e2794. https://doi.org/10.1136/bmj.e2794
47. 47. Sammon CJ, Snowball J, McGrogan A, de Vries CS. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. PLoS One 2012;7:e51734. https://doi.org/10.1371/journal.pone.0051734
48. 48. Chambers CD, Johnson D, Xu R, et al; OTIS Collaborative Research Group. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine 2013;31:5026–32. https://doi.org/10.1016/j.vaccine.2013.08.097
49. 49. Irving SA, Kieke BA, Donahue JG, et al; Vaccine Safety Datalink. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet Gynecol 2013;121:159–65. https://doi.org/10.1097/AOG.0b013e318279f56f
50. 50. Huang WT, Tang FW, Yang SE, Chih YC, Chuang JH. Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan. Vaccine 2014;32:6463–8. https://doi.org/10.1016/j.vaccine.2014.09.054
51. 51. Ma F, Zhang L, Jiang R, et al. Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women. Clin Vaccine Immunol 2014;21:1282–7. https://doi.org/10.1128/CVI.00375-14
52. 52. Chambers CD, Johnson DL, Xu R, et al; OTIS Collaborative Research Group. Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine 2016;34:4443–9. https://doi.org/10.1016/j.vaccine.2016.06.054
53. 53. McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine 2015;33:2108–17. https://doi.org/10.1016/j.vaccine.2015.02.068
54. 54. Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis 2015;60:e11–9. https://doi.org/10.1093/cid/ciu915
55. 55. Donahue JG, Kieke BA, King JP, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. Vaccine 2017;35:5314–22. https://doi.org/10.1016/j.vaccine.2017.06.069
56. 56. CDC. Advisory Committee on Immunization Practices summary report: February 27–28, 2019 (meeting minutes). Atlanta, GA: US Department of Health and Human Services, CDC; 2019.
57. 57. DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009–2010 season. Vaccine 2013;31:861–6. https://doi.org/10.1016/j.vaccine.2012.12.013
58. 58. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014;371:635–45. https://doi.org/10.1056/NEJMoa1315727
59. 59. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP; DiazGranados CA. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine 2015;33:4565–71.
60. 60. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine 2015;33:4988–93. https://doi.org/10.1016/j.vaccine.2015.07.006
61. 61. Dunkle LM, Izikson R, Patriarca P, et al; PSC12 Study Team. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med 2017;376:2427–36. https://doi.org/10.1056/NEJMoa1608862
62. 62. Van Buynder PG, Konrad S, Van Buynder JL, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013;31:6122–8. https://doi.org/10.1016/j.vaccine.2013.07.059
63. 63. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172–80. https://doi.org/10.1086/599790
64. 64. US Food and Drug Administration. Clinical review: Fluad. Silver Spring, MD: US Food and Drug Administration; 2015.
65. 65. US Food and Drug Administration. Clinical review: Fluzone High-Dose. Silver Spring, MD: US Food and Drug Administration; 2014.
66. 66. Fluzone High-Dose [Package Insert]. Swiftwater, PA: Sanofi Pasetur; 2019.
67. 67. Young-Xu Y, Van Aalst R, Mahmud SM, et al. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among Veterans Health Administration patients. J Infect Dis 2018;217:1718–27. https://doi.org/10.1093/infdis/jiy088
68. 68. Shay DK, Chillarige Y, Kelman J, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012–2013 and 2013–2014. J Infect Dis 2017;215:510–7. https://doi.org/10.1093/infdis/jiw641
69. 69. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in U.S. residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 2015;15:293–300. https://doi.org/10.1016/S1473-3099(14)71087-4
70. 70. Richardson DM, Medvedeva EL, Roberts CB, Linkin DR; CDC Epicenter Program. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis 2015;61:171–6. https://doi.org/10.1093/cid/civ261
71. 71. Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med 2017;5:738–46. https://doi.org/10.1016/S2213-2600(17)30235-7
72. 72. Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines 2018;17:435–43. https://doi.org/10.1080/14760584.2018.1471989
73. 73. US Food and Drug Administration. Summary basis for regulatory action: Flublok Quadrivalent. Silver Spring, MD: US Food and Drug Administration; 2016.
74. 74. Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012;176:527–33. https://doi.org/10.1093/aje/kws313
75. 75. Lapi F, Marconi E, Simonetti M, et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev Vaccines 2019;18:663–70. https://doi.org/10.1080/14760584.2019.1622418
76. 76. Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf
77. 77. Rubin LG, Levin MJ, Ljungman P, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44–100. https://doi.org/10.1093/cid/cit684
78. 78. CDC. Influenza antiviral medications: summary for clinicians. Atlanta, GA: US Department of Health and Human Services, CDC. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
79. 79. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ 2009;339(sep15 3):b3680. https://doi.org/10.1136/bmj.b3680
80. 80. CDC. Advisory Committee on Immunization Practices summary report: June 20–21, 2012 (meeting minutes). Atlanta, GA: US Department of Health and Human Services, CDC; 2012.
81. 81. CDC. Advisory Committee on Immunization Practices summary report: June 19–20, 2013 (meeting minutes). Atlanta, GA: US Department of Health and Human Services, CDC; 2013.
82. 82. Uyeki TM, Zane SB, Bodnar UR, et al; Alaska/Yukon Territory Respiratory Outbreak Investigation Team. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect Dis 2003;36:1095–102. https://doi.org/10.1086/374053
83. 83. Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis 2005;40:1282–7. https://doi.org/10.1086/429243
84. 84. Ratnam I, Black J, Leder K, et al. Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia. J Clin Virol 2013;57:54–8. https://doi.org/10.1016/j.jcv.2013.01.008
85. 85. Millman AJ, Kornylo Duong K, Lafond K, Green NM, Lippold SA, Jhung MA. Influenza outbreaks among passengers and crew on two cruise ships: A recent account of preparedness and response to an everpresent challenge. J Travel Med 2015;22:306–11. https://doi.org/10.1111/jtm.12215
86. 86. Flumist Quadrivalent [Package Insert]. Gaithersburg, MD: MedImmune; 2019.
87. 87. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007;55:1499–507. https://doi.org/10.1111/j.1532-5415.2007.01397.x
88. 88. Levin MJ, Buchwald UK, Gardner J, et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine 2018;36:179–85. https://doi.org/10.1016/j.vaccine.2017.08.029
89. 89. Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012;19:1296–303. https://doi.org/10.1128/CVI.00176-12
90. 90. Schwarz TF, Flamaing J, Rümke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011;29:5195–202. https://doi.org/10.1016/j.vaccine.2011.05.031
91. 91. McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 2007;25:3464–74. https://doi.org/10.1016/j.vaccine.2006.12.047
92. 92. Nakashima K, Aoshima M, Ohfuji S, et al. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial. Hum Vaccin Immunother 2018;14:1923–30. https://doi.org/10.1080/21645515.2018.1455476
93. 93. Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine 2015;33:4647–52. https://doi.org/10.1016/j.vaccine.2015.05.003
94. 94. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. Obstet Gynecol 2015;126:1069–74. https://doi.org/10.1097/AOG.0000000000001066
95. 95. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr 2014;168:211–9. https://doi.org/10.1001/jamapediatrics.2013.4469
96. 96. Duffy J, Weintraub E, Hambidge SJ, et al; Vaccine Safety Datalink. Febrile seizure risk after vaccination in children 6 to 23 months. Pediatrics 2016;138:e20160320. https://doi.org/10.1542/peds.2016-0320
97. 97. Li R, Stewart B, McNeil MM, et al. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013–2014 and 2014–2015 seasons. Pharmacoepidemiol Drug Saf 2016;25:928–34. https://doi.org/10.1002/pds.3996
98. 98. Patterson JL, Carapetian SA, Hageman JR, Kelley KR. Febrile seizures. Pediatr Ann 2013;42:249–54. https://doi.org/10.3928/00904481-20131122-09
99. 99. Nolan T, Bernstein DI, Block SL, et al; LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008;121:508–16. https://doi.org/10.1542/peds.2007-1064
100. 100. Lum LC, Borja-Tabora CF, Breiman RF, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010;28:1566–74. https://doi.org/10.1016/j.vaccine.2009.11.054
101. 101. Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis 2017;216:1352–61.
102. 102. Flucelvax Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2019.
103. 103. Fluad [Package Insert]. Holly Springs, NC: Seqirus; 2019.
104. 104. Afluria Quadrivalent [Package Insert]. Parkville, Victoria, Australia: Seqirus; 2019.
105. 105. US Food and Drug Administration. Clinical review: Afluria Quadrivalent. Silver Spring, MD: US Food and Drug Administration; 2018.
106. 106. Statler VA, Albano FR, Airey J, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6–59 months of age: A phase 3, randomized, noninferiority study. Vaccine 2019;37:343–51. https://doi.org/10.1016/j.vaccine.2018.07.036
107. 107. Fluzone Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2019.
108. 108. US Food and Drug Administration. Clinical review: Fluzone Quadrivalent. Silver Spring, Maryland: US Food and Drug Administration; 2019.
109. 109. Health Resources and Services Administration. What you need to know about the National Vaccine Injury Compensation Program (VICP). Washington, DC: US Department of Health and Human Services, Health Resources and Services Administration; 2019. https://www.hrsa.gov/sites/default/files/hrsa/vaccine-compensation/resources/about-vaccine-injury-compensation-program-booklet.pdf